Introduction
The accurate classification of asthma severity and control is a definite challenge since they are conceptually related and some of the criteria used in their assessment overlap. The optimal control of asthma has been defined by the presence of minimal respiratory symptoms, no activity limitation, normal respiratory function, and absence of the need for rescue bronchodilator (1) (2) (3) . Current series of criteria in the assessment of the control of asthma were established by the Global Initiative for Asthma (GINA) and the Canadian Asthma Consensus Guidelines (2;3) and they include daytime and nocturnal symptoms, the occurrence of asthma exacerbations, the need for inhaled short-acting beta 2 -agonists (SABA), physical activity, absenteeism, and forced expiratory volume in one second (FEV 1 ) or peak expiratory flow (PEF) values. Different methods are advocated by various guidelines in the assessment of asthma severity (1) (2) (3) . The GINA guidelines as well as the US National Asthma Education and Prevention Program Consensus guidelines relative to the assessment of severity rely upon the evaluation of the disease's inherent symptoms in the patient and his or hers lung function before instigating any treatment relative to the assessment of its severity (1;2). However, the Canadian Asthma Consensus Guidelines assess asthma severity once the treatment has been instigated and rely upon a combination of factors, many of which overlap with measures of symptom control. These include pulmonary function tests, the treatment required to obtain asthma control, the history of hospital admissions, and life-threatening asthma attacks (3) .
The use of administrative health databases to perform epidemiologic studies in the field of asthma has widely expanded in recent years (4) (5) (6) . The unavailability of clinical parameters to measure the level of asthma severity and control has always been considered as one of the limitations of using administrative databases in this field of research. Therefore, the development of an index of asthma severity and an index of asthma control based on electronically-available data seems necessary. Indeed, it is important to be able to measure asthma severity and control separately since, for example, in some studies it might be required to evaluate the control of asthma following a new treatment strategy, while in other studies it might be required to measure the level of severity of asthma before starting a new treatment.
Several validated multidimensional indexes of asthma control and severity have been developed for use in epidemiologic and clinical studies (7) (8) (9) (10) (11) (12) . These indexes are usually based on one or several factors that are considered clinically important in the assessment of asthma severity and control; for example, frequency, duration & intensity of symptoms, and pulmonary function tests. However and to the best of our knowledge, none of these indexes rely solely on data that are usually recorded in administrative health databases.
Therefore, the aim of this study was to develop and validate two database indexes, one to measure the control of asthma and the other to measure the severity of asthma in currently treated asthmatics using information related to dispensed asthma medications and medical services, which were obtained from the administrative healthcare databases of the Canadian province of Quebec.
Methods

Source of Data
Our database indexes of asthma severity and control are based upon variables that were recorded in two administrative databases of the Province of Quebec, Canada; Régie de l'AssuranceMaladie du Québec (RAMQ) and MED-ECHO. The RAMQ database provides information on medical services dispensed to all residents of Quebec and on prescribed medications provided to residents covered by the RAMQ's Prescription Drug Insurance Plan. Approximately 43% of the population of Quebec are covered by the RAMQ's Prescription Drug Insurance Plan and mainly include the elderly, social aid recipients since 1980, and about 1.7 million new adherents since 1997, mostly workers and their families who in socio-economic terms, represent the average population (13) . The RAMQ's Prescription Drug Insurance Plan database provides information on dispensed medications (date of filling, name, dose, quantity, dosage form and duration of the prescription) while the RAMQ's Medical Services database provides information on medical services dispensed in a clinic, an emergency department (ED), or a hospital (date, and diagnosis coded with ICD-9). The RAMQ's databases also provide socio-demographic data such as age, gender, social aid status and where relevant, date of death. Data recorded in the RAMQ's Prescription Drug Insurance database and asthma diagnoses recorded in the RAMQ's Medical Services database have been formally evaluated and deemed valid (14;15).
The MED-ECHO database is a provincial database, which records data on acute care hospitalizations and covers all residents of Quebec. For each hospitalization, we obtained data on primary & up to 15 secondary discharge diagnoses, date of admission, duration of hospital stay as well as the treatments received during the hospitalization (15) .
Description of the Database Indexes of Asthma Severity and Control
The database indexes of asthma severity and control that we developed are based upon the criteria detailed in the Canadian Asthma Consensus Guidelines for the assessment of the severity and control of asthmatic patients, who are already taking anti-asthmatic medications (3) . Three levels of asthma severity and two levels of asthma control were defined over a 12-month period based upon the following: the average daily dose of inhaled corticosteroid (ICS) in beclomethasone-chloroflurocarbon (CFC) equivalent, the use of additional controller therapies defined as at least 6 filled prescriptions of inhaled long-acting beta 2 -agonists, theophylline, or leukotriene-receptor antagonists within a 12-month period, the average number of doses of SABA per week, and the presence of markers of moderate to severe asthma exacerbations -a filled prescription of oral corticosteroids, an ED visit for asthma, or a hospitalization for asthma (16) . The details of the two database indexes are presented in Table 1 . Briefly, the mild asthma category corresponds to doses of ICS ranging from 0 to 500 µ g per day for patients who do not have an additional controller therapy, and doses of ICS ranging from 0 to 250 µ g per day for patients who have an additional controller therapy. Moreover, in order to be classified in this mild category, a patient must not have had a marker of a moderate to severe asthma exacerbation and nor have used more than an average of 3 doses of SABA per week during the 12-month period under study. The moderate asthma category corresponds to ICS doses larger than 500 µ g per day for patients who do not have an additional controller therapy, and doses larger than 250 µ g per day for patients who have an additional controller therapy, except for patients with high use of SABA and moderate to severe asthma exacerbations. Severe asthma is mainly characterized by doses of ICS that are greater than 1000 µ g per day, except for patients with both markers of group.bmj.com on June 24, 2017 -Published by http://thorax.bmj.com/ Downloaded from uncontrolled asthma; for example, patients who are taking more than 10 doses of SABA per week and a marker for a moderate to severe asthma exacerbation.
Patients were considered as controlled if they had no marker for moderate to severe asthma exacerbation and were taking no more than 3 doses of SABA per week for mild asthma and 10 doses of SABA per week for moderate and severe asthma.
Using data from the RAMQ's databases, an algorithm was developed to calculate the mean daily dose of ICS and the mean weekly dose of SABA on the basis of prescription renewals, quantity of medication dispensed, duration of the prescription, and time intervals between renewals (17;18). In order to calculate the equivalence of the mean daily dose of ICS into beclomethasone-CFC, we used the equivalency table published in the Canadian Asthma Consensus Guidelines (3). The pharmacist established the equivalencies for SABA; for example, one dose of SABA was equivalent to two inhalations of salbutamol from a metered-dose inhaler (100µg/inhalation) (19) .
Validation of the Database Indexes of Asthma Severity and Control
In order to validate the database indexes of asthma severity and control, we applied the indexes of severity and control that we had created to the administrative database information available for a sample of asthmatic patients recruited in two different asthma clinics. We then compared the actual mean pulmonary function test values for these patients across the classification categories to determine if pulmonary function corresponded with our indexes of severity and control. All the patients had a confirmed diagnosis of asthma with no diagnosis of a chronic obstructive pulmonary disease (COPD). The information concerning the use of prescribed medications, the history of hospitalizations, and ED visits for asthma was obtained from the RAMQ and MED-ECHO databases for all patients. The data obtained from the RAMQ and MED-ECHO provided us with the necessary information to classify the severity and control of each patient using our database indexes.
Application of the Database Indexes of Asthma Severity and Control
Our database indexes of asthma severity and control were applied in a cohort of asthmatic patients from Quebec in order to obtain the distribution of asthma severity and control as classified by our indexes at a population level. The Quebec cohort was comprised of 139 283 person-years of follow-up of asthmatic patients aged from 14 to 44 years old, who were selected from RAMQ and MED-ECHO databases between January 1 st 1997 and December 31 st 2004 . In order to be included in the cohort, patients had to have been diagnosed with asthma at least once between January 1 st 1997 and December 31 st 2004. Furthermore, their medications must have been covered by the RAMQ Prescription Drug Insurance Plan for at least one year prior and one year after the index date; which was defined as, the coming January 1 st after having been diagnosed with asthma. Based upon the aforementioned conditions, we found all the nonoverlapping one-year periods that fulfilled our criteria. Therefore, a patient could contribute more than one episode of one year of follow-up into the cohort. The level of asthma severity and control was evaluated for each one-year period included in the cohort using our database indexes. The RAMQ provided us with the data on dispensed medications, medical services, and sociodemographic data while MED-ECHO provided us with data related to hospitalizations for all patients included in the cohort.
Comparison of the Distribution of Asthma Severity Levels across Different Study Populations and Severity Indexes
For validation purposes, the distribution of the severity levels found in the Quebec cohort using our database index of severity was compared to the distribution of the severity levels found in different populations worldwide using other severity indexes. The first severity index with which we compared ours was based on the GINA classification of symptoms and FEV 1 that was then applied in a sample of 4,362 asthmatic patients (51% female) aged from 16-45 years old, who had been examined by clinical specialists in private practice throughout France between May 3 rd and 28 th 1993 (20) . The second severity index with which we compared ours was also based on the measure of asthma severity reported in the GINA guidelines -frequency of symptoms -and was applied to a sample of 2509 asthmatic patients identified in the Asthma Insights and Reality (AIR) survey conducted in the United States in 1998 (21) . The third severity index with which we compared ours was based on patient's reported daily medication usage and was applied to a sample of 1279 asthmatic patients, who had completed a telephone questionnaire and had filled inhaler prescriptions in community pharmacies in Ontario, Canada (7).
Statistical Analysis
The differences in mean FEV 1 (percent predicted value) were compared between the levels of asthma severity and control within the sample of patients recruited at the asthma clinics. We also performed the same analysis stratified by age: < 45 and > 45 years old. A cutoff point of 45 years old was used for this stratified analysis since before the age of 45 the diagnosis of asthma is unlikely to be mixed with a diagnosis of COPD, while it is not necessarily the case after 45 years old. Moreover, 45 years old was the median age in the sample of patients from the clinics and patients younger than 45 years old would be more easily comparable to the patients in the Quebec cohort. The comparison of the FEV 1 /FVC ratio between levels of asthma severity and control was only completed for patients recruited at the Montreal Chest Institute. Using the Student's t-test for independent samples, two-tailed pair wise comparisons were performed and p-values smaller than 0.05 were considered significant. No adjustment for multiple testing was done. The distribution of the levels of asthma severity and control using our database indexes was estimated among the Quebec cohort of asthmatic patients. All statistical analyses were performed using SAS version 8.02.
Ethical considerations
The link between the data obtained from the RAMQ database, the MED-ECHO database and the medical chart was made with a unique patient's identifier (patient health number) which is included in each database and medical chart. This link was approved by the Commission d'accès à l'information du Québec. This research project was approved by the ethics board of the Hôpital du Sacré-Coeur de Montréal and the Montreal Chest Institute.
Results
Study Population Characteristics
In Table 2 , we present the characteristics of the populations under study; i.e. patients from the asthma clinics and the Quebec cohort. Mean age of the 139 283 person-years of asthmatic patients of the Quebec cohort was lower (30.3 yrs) than those from the asthma clinics (49.0 yrs). Patients from the asthma clinics used more ICS than those from the Quebec cohort (71.8% vs. 63.0%). The use of more than 10 doses of SABA per week was higher among patients from the asthma clinics than patients in the Quebec cohort (26.8% vs. 24.0%). In the sample of patients from the asthma clinics, 11.3% had at least one ED visit and 4.2% had at least one hospitalization for asthma over a 12-month period, while these figures were 18.1% and 6.2% for patients in the Quebec cohort.
Application of our Database Index of Asthma Severity and Control
In Table 3 , we present the distribution of the levels of asthma severity and control based on our database indexes for the sample of 71 patients from the asthma clinics and the Quebec cohort. In patients from the asthma clinics, we found that 35 (49.3%), 21 (29.6 %), and 15 (21.1%) of them respectively had mild, moderate and severe asthma. Overall, in the asthma clinic sample, we classified 46.5% of patients as having poorly controlled asthma, and we found that of those we classified as mild, moderate or severe, 20.0 %, 57.1 % and 93.3 % respectively had poorly controlled asthma by our criteria. When this sample was stratified by age, we observed that younger patients were more likely to have mild asthma and controlled asthma than older patients. In the Quebec cohort, we found that 63.4%, 22.6%, and 14.0% respectively had mild, moderate and severe asthma and that 54.5 % had uncontrolled asthma.
Validation of the Database Indexes of Asthma Severity and Control
In Table 4 , we present the results of the analyses performed to validate our database indexes against pulmonary function measures. With respect to the index of severity, among the 71 patients from the asthma clinics, the mean predicted value of FEV 1 was found to be 89.8% for mild, 74.1 % for moderate, and 61.5 % for severe asthma. All pair wise comparisons of FEV 1 between the three levels of asthma severity were found to be statistically significant (Pvalue=0.0066 for moderate vs. mild, P-value < 0.0001 for severe vs. mild and P-value=0.0333 for severe vs. moderate respectively). In the sample of 56 patients from the Montreal Chest Institute, the FEV 1 /FVC ratio ranged from 75.8 % for mild to 61.8 % for severe asthma. Pair wise comparisons of the ratio were found to be statistically significant when mild patients were compared to moderate (P-value=0.0056) and severe patients (P-value=0.0302), but the observed difference between moderate and severe patients was not found to be statistically significant (Pvalue=0.2049).
With respect to the index of control, we found that patients we classified as well controlled had a mean FEV 1 of 89.5 % and a FEV 1 /FVC ratio of 75.3% while corresponding figures were 67.3 % and 65.7 % for those we classified as poorly controlled, using different subsets of clinic patients for the FEV 1 and FEV 1 /FVC comparisons as described in the methods. Differences between controlled and uncontrolled patients were found to be statistically significant (P-value=< 0.0001 for differences in FEV 1 and P-value=0.0009 for differences in FEV 1 /FVC ratio).
In Table 5 , we present the results of the analysis comparing FEV 1 across the different levels of asthma severity and control stratified by age (< 45 and > 45 years old). Statistically significant differences were observed for all pair wise comparisons between severity levels except for the moderate to severe comparison in younger patients and the mild to moderate comparison in the older patients. Differences in FEV 1 between controlled and uncontrolled patients were found to be statistically significant in both subgroups.
Comparison of the Distribution of Asthma Severity among Different Populations
The comparison of the distribution of asthma severity in the Quebec cohort assessed against our database index and the distribution of asthma severity in other populations worldwide assessed against other severity indexes is presented in Table 6 . In the Quebec cohort, the distribution of severity levels was 63%, 23%, and 14% for mild, moderate and severe respectively. This distribution was similar to those of two of the three study populations: between 59% and 66% for mild, around 22% for moderate, and between 13% and 19% for severe. However, the Ontarian population had quite a different distribution of severity with 28% of mild, 49% of moderate, and 23% of severe patients.
Discussion
We have demonstrated that our database indexes of asthma severity and control correlate well with lung function measures, such as the FEV 1 and the FEV 1 /FVC ratio, which are reliable indices reflecting asthma severity and control (1;3). Moreover, the application of our database severity index to a population-based cohort of asthmatic patients led to a distribution of asthma severity similar to that found with other severity indexes applied in two of the three comparison samples.
The need to adjust for the level of asthma severity and control to minimize confounding is encountered in most of the epidemiologic studies carried out in the field of asthma. However, these disease characteristics are not always easy to measure because of the lack of clinical data, especially in the case of studies performed with administrative databases. To the best of our knowledge, our indexes of asthma severity and control are the first of this kind to be entirely based on data available from health administrative databases, and it will be possible to use them in future epidemiologic studies in the field of asthma.
Differences in the distribution of asthma severity and control found in the populations that we studied are worthy of comments. Patients followed in asthma clinics of tertiary healthcare centers are more likely to have moderate or severe asthma and are more properly controlled due to the fact that they benefit from follow up from respiratory specialists. Our results do reflect this since the percentage of controlled patients in each level of severity was greater among the patients from the asthma clinics than those from the Quebec cohort. Moreover, we found that patients treated in the asthma clinics more commonly suffer from severe asthma, according to our criteria, than patients in the Quebec cohort.
Our results also demonstrated that the distribution of the level of asthma severity obtained by applying our database index to the Quebec cohort was close to the distribution found within two of the three asthma severity indexes based upon the symptoms and pulmonary function that have been applied in other populations, France and the United States (20;21). The distribution of severity found in the study conducted in Ontario was different from the one found in the Quebec cohort and this might be due to differences in how we define severity. According to the Ontarian index, patients were classified as having mild asthma if they had only bronchodilators to treat asthma, and they were classified as having moderate or severe asthma when they were prescribed ICS, while in our index of severity, patients with a low dose of ICS could be classified as having mild asthma. Indeed, the other two indexes resemble more than the Ontarian one to our indexes.
This study has some limitations that should be kept in mind when interpreting the results. First, with our database indexes it could, in some cases, be difficult to precisely distinguish the difference between asthma severity and control since the markers of exacerbations and use of rescue medications were used in both definitions. The overlap in the definitions of asthma severity and control could also result in an asthma that is more uncontrolled among severe patients than mild ones. This overlap could also have played a role in the validation against FEV 1 and FEV 1 /FVC measures for the asthma clinic sample since these pulmonary function values may reflect both severity and control. However, the difficulty in making a clear distinction between asthma severity and control is not specific to our indexes and is also encountered in clinical practice (22) . Second, our database index of severity was developed to measure disease severity among patients already treated for asthma and is at least in part based on the level of medication needed to attain control (3). Moreover, our indexes were validated among patients likely to be compliant to their treatment, because they were under the care of respiratory specialists. However and with respect to general clinical practice, a proportion of patients will not attain control and this might reduce the capacity of our severity index to accurately classify patients. Third, our database index of control cannot detect short-term changes since it is based on medications and health care services dispensed over a one-year period. Fourth, another limit of our study concerns the use of a single measure of lung function to validate the indexes. Only one measure of lung function might not be optimal to assess a parameter that can fluctuate over time. Moreover, since the FEV 1 /FVC ratio was available only for a subset of the patients from the clinics, we were not able to perform the age-stratified analysis for this measure. Fifth, patients included in the Quebec cohort are not fully representative of the population since they do not include patients with private drug insurance plans and tend to over represent patients with a low to moderate socioeconomic status.
This study has also several strengths. The database indexes can assess asthma severity and control among patients already treated for asthma and are at least in part based on the use of acute care for asthma, which are well-recognized markers of asthma severity and lack of control (3). Moreover, the data obtained from the Prescription Drug Insurance database regarding the mean dose of ICS and SABA are considered to be good reflection of usual dosage (23) (24) (25) (26) (27) . Our indexes were validated against pulmonary function measures that are well established measures of asthma severity and control. Moreover, the age-stratified analysis allowed us to assess the validity of our database index across different age groups. Finally, the distribution of asthma severity found with our database index when applied to the Quebec cohort was found to be comparable to the distribution of severity assessed with other indexes applied to two of the three different population samples we used for comparison.
In conclusion, we have demonstrated that the database indexes that we developed based on dispensed asthma medications and medical services are valid to the extent we could test this and could adequately classify currently treated asthmatic patients into categories of severity and control. In the absence of clinical data, our database indexes could be used in epidemiologic studies using administrative databases to reasonably assess the severity and control of asthma among adult patients and thus, improve the quality of database studies in the field of asthma.
Further research will be needed to confirm these findings, and to adapt and validate these database indexes for use in special populations including pregnant women, the elderly or pediatric patients. 
